Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR

Journal of Clinical Investigation

Volumn 122, Issue 1, 2012, Pages 241-252

  Schoppy, David W ^a   Ragland, Ryan L ^a   Gilad, Oren ^a   Shastri, Nishita ^a   Peters, Ashley A ^a   Murga, Matilde ^b   Fernandez Capetillo, Oscar ^b   Diehl, J Alan ^a   Brown, Eric J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; HYGROMYCIN; MIXED LINEAGE LEUKEMIA PROTEIN; PENICILLIN G; PROTEIN P53; PUROMYCIN; STREPTOMYCIN; TAMOXIFEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; C57BL 6 MOUSE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; FIBROSARCOMA; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; GENOMIC INSTABILITY; HOMEOSTASIS; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MOUSE; MYELOID LEUKEMIA; NEOPLASM; NONHUMAN; ONCOGENE C MYC; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL CYCLE PROTEINS; DNA DAMAGE; FIBROSARCOMA; GENES, P53; GENES, RAS; HOMEOSTASIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; MICE, TRANSGENIC; MUTATION; NEOPLASMS, EXPERIMENTAL; ONCOGENES; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; STRESS, PHYSIOLOGICAL;

EID: 84855418471     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI58928     Document Type: Article

References (64)

1. Paulsen RD, Cimprich KA. The ATR pathway: fine-tuning the fork. DNA Repair (Amst). 2007;6(7):953-966. (Pubitemid 46880476)
2. Nghiem P, Park PK, Kim Y, Vaziri C, Schreiber SL. ATR inhibition selectively sensitizes G1 checkpoint- deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci U S A. 2001;98(16):9092-9097. (Pubitemid 32743874)
3. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A, O'Connell MJ. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene. 2001;20(51):7453-7463. (Pubitemid 33086904)
4. Nghiem P, Park PK, Kim YS, Desai BN, Schreiber SL. ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem. 2002;277(6):4428-4434. (Pubitemid 34968710)
5. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer. 2004;4(3):216-225. (Pubitemid 38337501)
6. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med. 2011;17(2):88-96.
7. Toledo LI, Murga M, Fernandez-Capetillo O. Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol. 2011;5(4):368-373.
8. Ruzankina Y, Schoppy DW, Asare A, Clark CE, Vonderheide RH, Brown EJ. Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nat Genet. 2009;41(10):1144-1149.
9. Greenow KR, Clarke AR, Jones RH. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene. 2009;28(11):1443-1453.
10. Yazinski SA, Westcott PM, Ong K, Pinkas J, Peters RM, Weiss RS. Dual inactivation of Hus1 and p53 in the mouse mammary gland results in accumulation of damaged cells and impaired tissue regeneration. Proc Natl Acad Sci U S A. 2009;106(50):21282-21287.
11. Schoppy DW, Ruzankina Y, Brown EJ. Removing all obstacles: a critical role for p53 in promoting tissue renewal. Cell Cycle. 2010;9(7):1313-1319.
12. Murga M, et al. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat Genet. 2009;41(8):891-898.
13. Tanaka S, Diffley JF. Deregulated G1-cyclin expression induces genomic instability by preventing efficient pre-RC formation. Genes Dev. 2002;16(20):2639-2649.
14. Ekholm-Reed S, Mendez J, Tedesco D, Zetterberg A, Stillman B, Reed SI. Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J Cell Biol. 2004;165(6):789-800. (Pubitemid 38821970)
15. Bartkova J, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434(7035):864-870. (Pubitemid 40558993)
16. Gorgoulis VG, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434(7035):907-913. (Pubitemid 40559004)
17. Bartkova J, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444(7119):633-637. (Pubitemid 44864442)
18. Di Micco R, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyperreplication. Nature. 2006;444(7119):638-642. (Pubitemid 44864443)
19. Abulaiti A, Fikaris AJ, Tsygankova OM, Meinkoth JL. Ras induces chromosome instability and abrogation of the DNA damage response. Cancer Res. 2006;66(21):10505-10512. (Pubitemid 44799772)
20. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319(5868):1352-1355. (Pubitemid 351354863)
21. Loeb KR, et al. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell. 2005;8(1):35-47. (Pubitemid 40991813)
22. Mailand N, Diffley JFX. CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell. 2005;122(6):915-926. (Pubitemid 41345208)
23. Gilad O, et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 2010;70(23):9693-9702.
24. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689-698.
25. Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 2000;14(4):397-402. (Pubitemid 30131885)
26. Liu Q, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 2000;14(12):1448-1459. (Pubitemid 30421838)
27. Takai H, et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev. 2000;14(12):1439-1447. (Pubitemid 30421837)
28. de Klein A, et al. Targeted disruption of the cellcycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr Biol. 2000;10(8):479-482.
29. Brown EJ, Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev. 2003;17(5):615-628. (Pubitemid 36307546)
30. Lam MH, Liu Q, Elledge SJ, Rosen JM. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell. 2004;6(1):45-59. (Pubitemid 38903161)
31. Ruzankina Y, et al. Deletion of the developmentally essential gene ATR in adult mice leads to agerelated phenotypes and stem cell loss. Cell Stem Cell. 2007;1(1):113-126. (Pubitemid 46865802)
32. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet. 2003;33(4):497-501. (Pubitemid 36390012)
33. Zuber J, et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009;23(7):877-889.
34. Wiederschain D, Kawai H, Shilatifard A, Yuan ZM. Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage. J Biol Chem. 2005;280(26):24315-24321. (Pubitemid 40934513)
35. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009;9(10):701-713.
36. Toledo LI, et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol. 2011;18(6):721-727.
37. Reaper PM, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011;7(7):428-430.
38. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997;11(8):957-972. (Pubitemid 27199876)
39. Aggarwal P, et al. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev. 2007;21(22):2908-2922. (Pubitemid 350133439)
40. Charrier JD, et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J Med Chem. 2011;54(7):2320-2330.
41. Syljuasen RG, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol. 2005;25(9):3553-3562. (Pubitemid 40559562)
42. Smith KD, Fu MA, Brown EJ. Tim-Tipin dysfunction creates an indispensible reliance on the ATRChk1 pathway for continued DNA synthesis. J Cell Biol. 2009;187(1):15-23.
43. Davidson IF, Li A, Blow JJ. Deregulated replication licensing causes DNA fragmentation consistent with head-to-tail fork collision. Mol Cell. 2006;24(3):433-443. (Pubitemid 44647903)
44. Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene. 2008;27(50):6462-6472.
45. Liu H, et al. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature. 2010;467(7313):343-346.
46. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell. 2007;11(2):175-189. (Pubitemid 46209849)
47. Sarkisian CJ, et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol. 2007;9(5):493-505. (Pubitemid 46696530)
48. Feldser DM, et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature. 2010;468(7323):572-575.
49. Junttila MR, et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature. 2010;468(7323):567-571.
50. Kawasumi M, et al. Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase. Proc Natl Acad Sci U S A. 2011;108(33):13716-13721.
51. Tho LM, Libertini S, Rampling R, Sansom O, Gillespie DA. Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis [published online ahead of print August 1, 2011]. Oncogene. doi:10.1038/onc.2011.326.
52. Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells [published online ahead of print August 15, 2011]. Oncogene. doi:10.1038/onc.2011.358.
53. Menoyo A, Alazzouzi H, Espin E, Armengol M, Yamamoto H, Schwartz S Jr. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res. 2001;61(21):7727- 7730. (Pubitemid 33049356)
54. Vassileva V, Millar A, Briollais L, Chapman W, Bapat B. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res. 2002;62(14):4095-4099. (Pubitemid 34791080)
55. Fang Y, et al. ATR functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient background. EMBO J. 2004;23(15):3164-3174. (Pubitemid 39093610)
56. Tort F, et al. Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia. 2005;19(1):112-117. (Pubitemid 40090085)
57. Davies H, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005;65(17):7591-7595. (Pubitemid 41297230)
58. Lewis KA, et al. Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. Cancer Res. 2005;65(16):7091-7095. (Pubitemid 41161237)
59. Maniwa Y, et al. His239Arg SNP of HRAD9 is associated with lung adenocarcinoma. Cancer. 2006; 106(5):1117-1122.
60. Kim CJ, et al. Chk1 frameshift mutation in sporadic and hereditary non-polyposis colorectal cancers with microsatellite instability. Eur J Surg Oncol. 2007;33(5):580-585. (Pubitemid 46746542)
61. Lewis KA, Bakkum-Gamez J, Loewen R, French AJ, Thibodeau SN, Cliby WA. Mutations in the ataxia telangiectasia and rad3-related-checkpoint kinase 1 DNA damage response axis in colon cancers. Genes Chromosomes Cancer. 2007;46(12):1061-1068. (Pubitemid 47614540)
62. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 2002;1(3):289-298. (Pubitemid 41039153)
63. Tuveson DA, et al. Endogenous oncogenic Kras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 2004;5(4):375-387. (Pubitemid 38482073)
64. Chanoux RA, Yin B, Urtishak KA, Asare A, Bassing CH, Brown EJ. ATR and H2AX cooperate in maintaining genome stability under replication stress. J Biol Chem. 2009;284(9):5994-6003.